Source-grounded facts extracted from Research Alliance Corp III's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Research Alliance Corp III entered into Letter Agreement with Research Alliance Holdings III LLC (the "Sponsor") and each of the officers and directors of the Company (effective 2026-05-19).
“A Letter Agreement, dated May 19, 2026, by and among the Company, the Sponsor, and each of the officers and directors of the Company”
Research Alliance Corp III entered into Registration and Shareholder Rights Agreement with Research Alliance Holdings III LLC (the "Sponsor") and the other parties thereto (effective 2026-05-19).
“A Registration and Shareholder Rights Agreement, dated May 19, 2026, by and among the Company, Research Alliance Holdings III LLC (the “Sponsor”) and the other parties thereto”
Research Alliance Corp III entered into Investment Management Trust Agreement with Continental Stock Transfer & Trust Company (effective 2026-05-19).
“An Investment Management Trust Agreement, dated May 19, 2026, between the Company and Continental Stock Transfer & Trust Company, which establishes the trust account that will hold the net proceeds of the IPO”
Research Alliance Corp III entered into Private Placement Shares Purchase Agreement with Research Alliance Holdings III LLC (the "Sponsor") (effective 2026-05-19).
“A Private Placement Shares Purchase Agreement, dated May 19, 2026, between the Company and the Sponsor, pursuant to which the Sponsor agreed to purchase 275,000 Class A ordinary shares (the “Private Placement Shares”) in a private placement by the Company at a price of $10.00 per Private Placement Share”
Research Alliance Corp III entered into Underwriting Agreement with Leerink Partners LLC (effective 2026-05-19).
“An Underwriting Agreement, dated May 19, 2026, between the Company and Leerink Partners LLC, as sole bookrunning manager of the offering”
Research Alliance Corp III: Adopted Amended and Restated Memorandum and Articles of Association in connection with IPO (effective 2026-05-19).
“On May 19, 2026, and in connection with the IPO, the Company adopted its Amended and Restated Memorandum and Articles of Association.”
Timothy J. Miller was appointed as Director at Research Alliance Corp III.
“Michael F. MacLean and Timothy J. Miller were appointed to the board of directors of the Company (the “Board”).”
Michael F. MacLean was appointed as Director at Research Alliance Corp III.
“Michael F. MacLean and Timothy J. Miller were appointed to the board of directors of the Company (the “Board”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.